Psychedelic mechanisms: what 5-HT2A research shows and what is still a hypothesis

**Research review** ## What is known, what is not, and the risks Classic psychedelics (psilocybin, LSD, DMT) are controlled in many countries. This article explains the mechanisms using published data. It gives no guidance on use, doses, combinations or sources. - **Known:** in experiments on cells and mice, activation of 5-HT2A receptors is needed for psychedelic-induced plasticity in the cortex, and receptors inside the cell play a key role [S-001]. In a 2006 double-blind study of volunteers given a high dose of psilocybin, there were acute perceptual changes, labile mood including anxiety, and mystical-type experiences. At two months, participants and observers reported lasting changes [S-002]. - **Unknown:** which mechanism drives long-term effects in people, and whether there is any therapeutic benefit for mood disorders. That remains a hypothesis; our sources contain no clinical data on it. - **Risks:** acute effects are hard to predict. Anxiety and difficult experiences were reported even under controlled conditions [S-002]. Do not start anything of this kind without talking to a doctor, especially with psychiatric or cardiovascular conditions or if you take other medicines. This is general caution: those groups were not analysed in our sources. This article does not claim these substances are safe or that they treat anything. ## The hook "Psychedelics rewire the brain" sounds like an answer to everything. Let us separate what has been tested from what is still a guess. ## In brief - Activation of 5-HT2A receptors is needed for psychedelic-induced plasticity in the cortex. According to this work, serotonin does not trigger the same mechanism [S-001]. - The 2023 paper highlights intracellular 5-HT2A receptors, not only those on the cell surface [S-001]. - In a controlled study, mystical-type experiences were followed by changes in attitudes and behaviour, rated at two months [S-002]. The post's "more than a year" is not supported and has been removed. ## What is known about the mechanism, and where the hypothesis starts The link to 5-HT2A receptors is the main working model for classic psychedelics, and experiments support it for cortical plasticity [S-001]. Beyond that, it is conjecture. The 2023 authors frame the rapid, sustained therapeutic effects as something that "has been hypothesized" to rest on new neuronal growth. That is a hypothesis, not a demonstrated mechanism [S-001]. The post also argued that subjective effects come from changes in brain network connectivity and a "loosening of high-level beliefs". Our sources do not test that, so it stays a [working hypothesis]. ## What the studies measured The 2023 study (S-001) used cells and mice, so its conclusions about people remain indirect. The authors show that the plasticity effect depends on where 5-HT2A receptors sit inside the cell, and that different agonists differ in whether they produce it. The 2006 study (S-002) was done in people. Participants who practised religious or spiritual activities received a high dose of psilocybin and an active control (methylphenidate) in a double-blind design. Two months later, participants rated the experience's personal meaning, and observers rated changes in behaviour. The post does not name this study. We matched it to the two-month claim as the closest fit. That is our identification, not a citation from the post. ## What comes next The blog has no products or protocols on this topic. If your question concerns mental health, talk to a doctor or psychiatrist. This article does not lead to a purchase. ## A question for readers For you, what matters more in this topic: understanding the mechanism, or the fact that it has not been proven in people? ## What was checked and what was meant | Claim | Status | Source | |---|---|---| | Activation of 5-HT2A is needed for psychedelic-induced plasticity in the cortex | checked against the Science 379:700–706 abstract (experiments on cells and mice) | S-001 | | Intracellular 5-HT2A mediate plasticity; serotonin does not trigger the same mechanism | checked against the abstract; full text not opened | S-001 | | Therapeutic effects are linked to new neuronal growth | hypothesis, as the 2023 authors phrase it | S-001 | | Acute perceptual changes, labile mood including anxiety, and mystical-type experiences after psilocybin | checked against the abstract (human study, 2006) | S-002 | | At two months, participants and observers reported lasting changes | checked against the abstract; the assessment was at two months, not longer | S-002 | | Mystical experiences last months to more than a year | not supported: S-002 assessed at two months; "more than a year" removed | — | | Subjective effects are explained by network connectivity and "loosening of beliefs" | working hypothesis from the post; not tested in our sources | — | | Psychedelics treat mood disorders | not supported; no clinical data in our sources; claim removed | — | | References to Carhart-Harris | not identified; not used | — | | Author's personal experience | not provided in the materials; no block added | — | Author: Serge Luboff. Reviewer: not assigned. Medical review: not carried out. This is not medical advice and does not replace a consultation with a doctor.